Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?

American Journal of Obstetrics and Gynecology

Volumn 197, Issue 3, 2007, Pages 260.e1-260.e4

  How, Helen Y ^a   Barton, John R ^b   Istwan, Niki B ^c   Rhea, Debbie J ^c   Stanziano, Gary J ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CENTRAL BAPTIST HOSPITAL   (United States)

^c Matria Healthcare Inc   (United States)

Author keywords

17 alpha hydroxyprogesterone caproate prophylaxis; preterm delivery

Indexed keywords

HYDROXYPROGESTERONE CAPROATE;

ADULT; ARTICLE; CONTROLLED STUDY; DELIVERY; DRUG EFFICACY; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREMATURE LABOR; PRIORITY JOURNAL; PROPHYLAXIS;

EID: 34548421118     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.07.013     Document Type: Article

References (12)

1. Callaghan W.M., MacDorman M.F., Rasmussen S.A., et al. The contribution of preterm birth to infant mortality rates in the United States. Pediatrics 118 (2006) 1566-1573
2. Paneth N.S. The problem of low birth weight. Future Childs 5 (1995) 19-34
3. Tucker J.M., and Goldenberg R.L. Etiologies of preterm birth in an indigent population: is prevention a logical expectation?. Obstetric Gynecol 77 (1991) 343-347
4. Bakketeig L.S., and Hoffman H.J. Epidemiology of preterm birth: results from a longitudinal study of births in Norway. In: Elder M.G., and Hendricks C.H. (Eds). Preterm labor (1981), Butterworths, Boston 17-46
5. Mercer B.M., Goldenberg R.L., Moawad A.H., et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 181 (1999) 1216-1221 5 Pt 1
6. Meis P.J., Klebanoff M., Thom E., et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 348 (2003) 2379-2385
7. Gonzalez-Quintero V.H., Istwan N.B., Rhea D.J., Smarkusky L., Hoffman M.C., and Stanziano G.J. Gestational age at initiation of 17a-hydroxyprogesterone caproate (17P) and recurrent preterm delivery. J Matern Fetal Neonatal Med 20 (2007) 249-252
8. Csapo A.I., Pulkkinen M.O., Ruttner B., Sauvage J.P., and Wiest W.G. The significance of human corpus luteum in pregnancy maintenance. 1. Preliminary studies. Am J Obstet Gynecol 112 (1972) 1061-1067
9. Csapo A.I., Henzl M.R., Kaihola H.L., Kivikoski, and Pulkkinen M.O. Suppression of uterine activity and abortion by inhibition of prostaglandin synthesis. Prostaglandins 7 (1974) 39-47
10. Csapo A.I., Pohanka O., and Kaihola H.L. Progesterone deficiency and premature labour. BMJ i (1974) 137-140
11. da Fonseca E.B., Bittar R.E., Carvalho M.H.B., and Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double blind study. Am J Obstet Gynecol 188 (2003) 419-424
12. Spong C.Y., Meis P.J., Thom E.A., et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. Am J Obstet Gynecol 193 (2005) 1127-1131